Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2

被引：3
|
作者：
Temel, Jennifer S.
Currow, David Christopher
Fearon, Kenneth
Yan, Ying
Friend, John
Abernethy, Amy Pickar
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Flinders Univ S Australia, Adelaide, SA 5001, Australia
[3] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[4] Helsinn Therapeut Inc, Iselin, NJ USA
[5] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 29期
关键词：
D O I：
10.1200/jco.2015.33.29_suppl.175
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
175
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A single center experience of anamorelin in patients with non-small cell lung cancer
    Ito, T.
    Fujita, K.
    Imakita, T.
    Kanai, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1637 - S1637
  • [22] Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis
    Nishie, Kenichi
    Yamamoto, Shuhei
    Nagata, Chie
    Koizumi, Tomonobu
    Hanaoka, Masayuki
    LUNG CANCER, 2017, 112 : 25 - 34
  • [23] Body weight (BW) response timing to anamorelin (ANAM) in advanced non-small cell lung cancer (NSCLC)-associated cachexia.
    Skipworth, Richard J. E.
    Walsh, Declan
    Rotaru, Daniela D.
    Ballinari, Gianluca
    Currow, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
    Arai, D.
    Kido, R.
    Yamaguchi, J.
    Kamimoto, S.
    Furuya, S.
    Kanzawa, A.
    Miyazaki, M.
    Baba, R.
    Okamori, S.
    Takahashi, H.
    Nakachi, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1638 - S1639
  • [25] Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
    Jo, Hitomi
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Yagishita, Shigehiro
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Yamamoto, Noboru
    Takahashi, Kazuhisa
    Motoi, Noriko
    Ohe, Yuichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (02) : 387 - 398
  • [26] Efficacy of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia and modified Glasgow Prognostic Score (mGPS) of 2: Pooled analysis of two phase 3 trials
    Kaasa, S.
    Laird, B.
    Fallon, M.
    McMillan, D.
    Skipworth, R.
    Currow, D.
    Giorgino, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
    Hitomi Jo
    Tatsuya Yoshida
    Hidehito Horinouchi
    Shigehiro Yagishita
    Yuji Matsumoto
    Yuki Shinno
    Yusuke Okuma
    Yasushi Goto
    Noboru Yamamoto
    Kazuhisa Takahashi
    Noriko Motoi
    Yuichiro Ohe
    Cancer Immunology, Immunotherapy, 2022, 71 : 387 - 398
  • [28] Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion
    Currow, David C.
    Maddocks, Matthew
    Cella, David
    Muscaritoli, Maurizio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [29] Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
    Koichi Takayama
    Shinji Atagi
    Fumio Imamura
    Hiroshi Tanaka
    Koichi Minato
    Toshiyuki Harada
    Nobuyuki Katakami
    Takuma Yokoyama
    Kozo Yoshimori
    Yuichi Takiguchi
    Osamu Hataji
    Yuichiro Takeda
    Keisuke Aoe
    Young Hak Kim
    Soichiro Yokota
    Hiroshi Tabeta
    Keisuke Tomii
    Yasuo Ohashi
    Kenji Eguchi
    Koshiro Watanabe
    Supportive Care in Cancer, 2016, 24 : 3473 - 3480
  • [30] The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review
    Morita-Tanaka, Satomi
    Yamada, Tadaaki
    Takayama, Koichi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (01) : 168 - 180
12345